Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival

Molecular and Cellular Endocrinology

Volumn 349, Issue 2, 2012, Pages 281-288

  Nakashima, Koji ^a,b   Shimoda, Masashi ^a   Hamamoto, Sumiko ^a   Tatsumi, Fuminori ^a   Hirukawa, Hidenori ^a   Tawaramoto, Kazuhito ^a   Kanda, Yukiko ^a   Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Department of Cardiovascular Surgery   (Japan)

Author keywords

Apoptosis; Autocrine; Exendin 4; Glucagon like peptide 1 (GLP 1); Insulin; MIN6

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; EXENDIN 4; EXENDIN 9; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; MESSENGER RNA; PROGLUCAGON DERIVATIVE; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 3; SERINE PROTEINASE; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; CREBBP PROTEIN, HUMAN; EXENDIN (9 39); EXENDIN (9-39); EYE PROTEIN; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; GLUCOSE; HOMEODOMAIN PROTEIN; INSULIN; NEUTRALIZING ANTIBODY; PAIRED BOX TRANSCRIPTION FACTOR; PANCREATIC AND DUODENAL HOMEOBOX 1 PROTEIN; PEPTIDE; PEPTIDE FRAGMENT; PROGLUCAGON; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN; VENOM;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUCAGON RELEASE; IMMEDIATE EARLY GENE; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; NUCLEOTIDE SEQUENCE; ONTOGENY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN FUNCTION; RNA SEQUENCE; UPREGULATION; BIOSYNTHESIS; CELL LINE; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; SECRETION; SIGNAL TRANSDUCTION;

ANTIBODIES, NEUTRALIZING; APOPTOSIS; AUTOCRINE COMMUNICATION; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CREB-BINDING PROTEIN; EYE PROTEINS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HOMEODOMAIN PROTEINS; HUMANS; INSULIN; MICROSCOPY, CONFOCAL; PAIRED BOX TRANSCRIPTION FACTORS; PEPTIDE FRAGMENTS; PEPTIDES; PROGLUCAGON; RECEPTORS, GLUCAGON; REPRESSOR PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; VENOMS;

EID: 84862611349     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.11.008     Document Type: Article

References (33)

1. Ahren B., Pacini G., Foley J.E., Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28:1936-1940.
2. Alarcon C., Wicksteed B., Rhodes C.J. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 2006, 49:2920-2929.
3. Aramata S., Han S.I., Kataoka K. Roles and regulation of transcription factor MafA in islet beta-cells. Endocr. J. 2007, 54:659-666.
4. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
5. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
6. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
7. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 2003, 17:161-171.
8. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA 1987, 84:3434-3438.
9. Glauser D.A., Brun T., Gauthier B.R., Schlegel W. Transcriptional response of pancreatic beta cells to metabolic stimulation: large scale identification of immediate-early and secondary response genes. BMC Mol. Biol. 2007, 8:54.
10. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 1993, 268:19650-19655.
11. Heller R.S., Aponte G.W. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36) amide. Am. J. Physiol. 1995, 269:G852-G860.
12. Hui H., Nourparvar A., Zhao X., Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003, 144:1444-1455.
13. Hussain M.A., Porras D.L., Rowe M.H., West J.R., Song W.J., Schreiber W.E., Wondisford F.E. Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation. Mol. Cell Biol. 2006, 26:7747-7759.
14. Kedees M.H., Grigoryan M., Guz Y., Teitelman G. Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia. Mol. Cell Endocrinol. 2009, 311:69-76.
15. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 2:1300-1304.
16. Li Y., Cao X., Li L.X., Brubaker P.L., Edlund H., Drucker D.J. Beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005, 54:482-491.
17. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003, 278:471-478.
18. Masur K., Tibaduiza E.C., Chen C., Ligon B., Beinborn M. Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function. Mol. Endocrinol. 2005, 19:1373-1382.
19. Miyazaki J., Araki K., Yamato E., Ikegami H., Asano T., Shibasaki Y., Oka Y., Yamamura K. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 1990, 127:126-132.
20. Nakashima K., Kanda Y., Hirokawa Y., Kawasaki F., Matsuki M., Kaku K. MIN6 is not a pure beta cell line but a mixed cell line with other pancreatic endocrine hormones. Endocr. J. 2009, 56:45-53.
21. Rothenberg M.E., Eilertson C.D., Klein K., Zhou Y., Lindberg I., McDonald J.K., Mackin R.B., Noe B.D. Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro. J. Biol. Chem. 1995, 270:10136-10146.
22. Seino Y., Rasmussen M.F., Zdravkovic M., Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2008, 81:161-168.
23. Serre V., Dolci W., Schaerer E., Scrocchi L., Drucker D., Efrat S., Thorens B. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence. Endocrinology 1998, 139:4448-4454.
24. Shimoda M., Kanda Y., Hamamoto S., Tawaramoto K., Hashiramoto M., Matsuki M., Kaku K. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011, 54:1098-1108.
25. Thorel F., Nepote V., Avril I., Kohno K., Desgraz R., Chera S., Herrera P.L. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 2010, 464:1149-1154.
26. Thyssen S., Arany E., Hill D.J. Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 2006, 147:2346-2356.
27. Tornehave D., Kristensen P., Romer J., Knudsen L.B., Heller R.S. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J. Histochem. Cytochem. 2008, 56:841-851.
28. Trinh D.K., Zhang K., Hossain M., Brubaker P.L., Drucker D.J. Pax-6 activates endogenous proglucagon gene expression in the rodent gastrointestinal epithelium. Diabetes 2003, 52:425-433.
29. Tsunekawa S., Yamamoto N., Tsukamoto K., Itoh Y., Kaneko Y., Kimura T., Ariyoshi Y., Miura Y., Oiso Y., Niki I. Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. J. Endocrinol. 2007, 193:65-74.
30. Wen J.H., Chen Y.Y., Song S.J., Ding J., Gao Y., Hu Q.K., Feng R.P., Liu Y.Z., Ren G.C., Zhang C.Y., Hong T.P., Gao X., Li L.S. Paired box 6 (PAX6) regulates glucose metabolism via proinsulin processing mediated by prohormone convertase 1/3 (PC1/3). Diabetologia 2009, 52:504-513.
31. Yue F., Cui L., Johkura K., Ogiwara N., Sasaki K. Glucagon-like peptide-1 differentiation of primate embryonic stem cells into insulin-producing cells. Tissue Eng. 2006, 12:2105-2116.
32. Yusta B., Baggio L.L., Estall J.L., Koehler J.A., Holland D.P., Li H., Pipeleers D., Ling Z., Drucker D.J. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006, 4:391-406.
33. Zanger K., Cohen L.E., Hashimoto K., Radovick S., Wondisford F.E. A novel mechanism for cyclic adenosine 3',5'-monophosphate regulation of gene expression by CREB-binding protein. Mol. Endocrinol. 1999, 13:268-275.